1
Enquiry period
with 22.08.2025 16:58
to 27.08.2025 16:00
4 days left
2
Bidding period
with 27.08.2025 16:00
to 08.09.2025 15:00
3
Auction
09.09.2025 15:00
4
Evaluation

5
Contract

Status Enquiry period
Estimated value without VAT 18 551,67 MDL
Period of clarifications: 22 Aug 2025, 16:58 - 27 Aug 2025, 16:00
Submission of proposals: 27 Aug 2025, 16:00 - 8 Sep 2025, 15:00

Supplier technical support:

(+373) 79999801

Advertising
Subscribe
Advertising

În scopul atribuirii contractelor subsecvente (pentru anul 2026) ca urmare a acordului-cadru nr. ocds-b3wdp1-MD-1722343095357 din 29.08.2024 încheiat prin procedura de achiziție publică nr. ocds-b3wdp1-MD-1722343095357 din 09.08.2024 privind „Achiziţionarea medicamentelor pentru tratarea pacienților cu maladia Wilson Konovalov în scopul realizării Programului Național "Combaterea maladiilor rare" pentru anul 2025-2027 (repetat)”

Information about customer
Fiscal code/IDNO
Address
MD-2005, MOLDOVA, mun.Chişinău, locality, mun. Chișinău MD-2005, bd. Grigore Vieru, 22/2
Web site
---
The contact person
Full name
Macari Doina
Contact phone
+37322222490
Purchase data
Date created
22 Aug 2025, 16:52
Date modified
22 Aug 2025, 16:58
Achizitii.md ID
21469816
CPV
33600000-6 - Produse farmaceutice
Type of procedure
Request price offers (goods)
Award criteria
The lowest price
Funding sources
List of lots
Lot nr. 1 - Zinci sulfas 124 mg
Budget: 18551.67 MDL
Active
Advertising
Documents of the procurement procedure
Model contract subsecvent
Bidding Documents
Model contract subsecvent
22.08.25 16:58
Propunerea financiară
Technical Specifications
Propunerea financiară
22.08.25 16:58
Propunerea tehnică
Technical Specifications
Propunerea tehnică
22.08.25 16:58
declarație (1)
Bidding Documents
declarație (1)
22.08.25 16:58
AcordCadru_NR_ocds...95357.signed.semnat.signed
Bidding Documents
AcordCadru
22.08.25 16:58
Invitatie pentru reofertareee.signed
Bidding Documents
Invitatie pentru reofertareee.signed
22.08.25 16:58
Question's name
Question
Only authorized platform users may ask questions during the clarification period.